Valbiotis, a French Research & Development company committed to fighting against metabolic diseases, to prevention and to scientific innovation, has appointed Dr Christine Roy-Duval as Director of Development and Medical Affairs.
"We are honored to welcome Dr Christine Roy-Duval to Valbiotis. A leading expert in the pharmaceuticals sector, Dr Roy-Duval has acquired extensive international experience in Research and Development. Her background in the industry is invaluable to our company, which strives to develop products backed by very strong clinical evidence in order to obtain bold health claims in Europe and North America, and a potential reimbursement status from private insurance companies."
"Her contribution to our teams will be a great asset in reaching these objectives. Her expertise in the field of diabetes and cardiometabolic diseases is backed by a strong commitment to proposing effective prevention strategies, an approach at the core of our strategy," said Sébastien Peltier, CEO of Valbiotis.
Within the fast development of Valbiotis, Dr Roy-Duval will be responsible for Medical Affairs, with the primary mission to lead the clinical development of the product portfolio in relation with the relevant health authorities, namely the the United States Food and Drug Administration (FDA).
She will also be at the helm of the Market Access strategy to obtain reimbursement status from private insurance companies, particularly for Valedia. She will also help to build relations between Valbiotis and the medical and healthcare professionals community.
Dr Christine Roy-Duval, said: "Prevention is a key component of the fight against cardiometabolic diseases around the world. I am happy to bring my experience to Valbiotis to help develop a new type of product designed to reduce the risk factors of these diseases. Valbiotis is a young company dedicated to a scientific and human project, which I fully support and which has all the tools necessary to succeed."
Prior to joining Valbiotis, Dr Roy-Duval served as International Clinical Investigation Director for SANOFI's Diabetes since 2011. In this role, she contributed to the successful registration of two drugs developed to treat type-2 diabetes, particularly in the US, Canada, China and Europe.
In addition to her internationally renowned expertise in Research and Development, Dr Roy-Duval brings to the table more than 29 years of experience with various major pharmaceutical industry players (Synthelabo, Rhône-Poulenc Rorer, Aventis Pharma, SANOFI), where she held several senior and leadership positions.
Her in-depth knowledge of drug development and market authorisation processes, combined with 10 years of specialised experience in clinical development in the field of diabetes and metabolic diseases, is a major asset for Valbiotis's development and for marketing the various products in its portfolio.
Christine Roy-Duval is a Doctor of Medicine, a graduate of the Paris V Faculty of Medicine. She obtained her PhD from Paris XI University and a degree in dietetics and nutrition from the Paris V Faculty of Pharmacy.
